N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A.Yao, G., Zhang, S., Mahrhold, S., Lam, K.H., Stern, D., Bagramyan, K., Perry, K., Kalkum, M., Rummel, A., Dong, M., Jin, R.
(2016) Nat.Struct.Mol.Biol. 23: 656-662
- PubMed: 27294781
- DOI: 10.1038/nsmb.3245
- Primary Citation of Related Structures:
- PubMed Abstract:
Botulinum neurotoxin serotype A1 (BoNT/A1), a licensed drug widely used for medical and cosmetic applications, exerts its action by invading motoneurons. Here we report a 2.0-Å-resolution crystal structure of the BoNT/A1 receptor-binding domain in co ...
Botulinum neurotoxin serotype A1 (BoNT/A1), a licensed drug widely used for medical and cosmetic applications, exerts its action by invading motoneurons. Here we report a 2.0-Å-resolution crystal structure of the BoNT/A1 receptor-binding domain in complex with its neuronal receptor, glycosylated human SV2C. We found that the neuronal tropism of BoNT/A1 requires recognition of both the peptide moiety and an N-linked glycan on SV2. This N-glycan-which is conserved in all SV2 isoforms across vertebrates-is essential for BoNT/A1 binding to neurons and for its potent neurotoxicity. The glycan-binding interface on SV2 is targeted by a human BoNT/A1-neutralizing antibody currently licensed as an antibotulism drug. Our studies reveal a new paradigm of host-pathogen interactions, in which pathogens exploit conserved host post-translational modifications, thereby achieving highly specific receptor binding while also tolerating genetic changes across multiple isoforms of receptors.
Department of Physiology and Biophysics, University of California, Irvine, Irvine, California, USA.